1. Inoue K, Blumenthal DM, Elashoff D, Tsugawa Y. Association between physician characteristics and payments from industry in 2015-2017: observational study. BMJ Open. 2019. September20;9(9):e031010. [PMC free article] [PubMed] [Google Scholar]
2. Mitchell AP, Mishra AA, Dey P, Curry MA, Trivedi NA, Haddadin M, et al. The association between drug industry payments and NCCN guideline panel membership. J Clin Oncol. 2020. May20;38(15_suppl):2068–2068. [Google Scholar]
3. Robbins NM, Meyer MJ, Bernat JL. Scope and nature of financial conflicts of interest between neurologists and industry: 2013-2016. Neurology. 2019. September3;93(10):438–49. [PubMed] [Google Scholar]
4. Schlager E, Flaten H, St Claire C, Maxim E, Dunnick C, Dellavalle RP. Industry payments to dermatologists: updates from the 2016 open payment data. Dermatol Online J. 2018. 13;24(4). [PubMed] [Google Scholar]
5. Elsamadicy AA, Freedman IG, Koo AB, Reeves BC, Havlik J, David WB, et al. Characteristics of Reported Industry Payments to Neurosurgeons: A 5-Year Open Payments Database Study. World Neurosurg. 2020. October1; [PubMed] [Google Scholar]
6. The Facts About Open Payments Data: 2018 Totals[Internet].CMS; [cited 2020 Mar 28]. Available from: https://openpaymentsdata.cms.gov/summary
7. Schwartz LM, Woloshin S. Medical Marketing in the United States, 1997-2016. JAMA. 2019. January1;321(1):80–96. [PubMed] [Google Scholar]
8. Brennan TA, Rothman DJ, Blank L, Blumenthal D, Chimonas SC, Cohen JJ, et al. Health industry practices that create conflicts of interest: a policy proposal for academic medical centers. JAMA. 2006. January25;295(4):429–33. [PubMed] [Google Scholar]
9. Lichter AS. Conflict of Interest and the Integrity of the Medical Profession. JAMA. 2017. May2;317(17):1725–6. [PubMed] [Google Scholar]
10. Mitchell AP, Basch EM, Dusetzina SB. Financial Relationships With Industry Among National Comprehensive Cancer Network Guideline Authors. JAMA Oncol. 2016. August25;2(12):1628–31. [PubMed] [Google Scholar]
11. Carr D, Welch HG. Industry Payments to Physician Directors of National Cancer Institute-Designated Cancer Centers, 2015-2017. JAMA Intern Med. 2019. August5;179(11):1595–7. [PMC free article] [PubMed] [Google Scholar]
12. Gill J, Haslam A, Crain T, Herrera-Perez D, Prasad V. Comparison of Industry Payments in 2017 With Annual Salary in a Cohort of Academic Oncologists. JAMA Intern Med. 2020. March23;180(5):797–9. [PMC free article] [PubMed] [Google Scholar]
13. Samuel AM, Webb ML, Lukasiewicz AM, Bohl DD, Basques BA, Russo GS, et al. Orthopaedic Surgeons Receive the Most Industry Payments to Physicians but Large Disparities are Seen in Sunshine Act Data. Clin Orthop. 2015. October;473(10):3297–306. [PMC free article] [PubMed] [Google Scholar]
14. Tringale KR, Marshall D, Mackey TK, Connor M, Murphy JD, Hattangadi-Gluth JA. Types and Distribution of Payments From Industry to Physicians in 2015. JAMA. 2017. May2;317(17):1774–84. [PMC free article] [PubMed] [Google Scholar]
15. Oldani MJ. Thick prescriptions: toward an interpretation of pharmaceutical sales practices. Med Anthropol Q. 2004. September;18(3):325–56. [PubMed] [Google Scholar]
16. Sah S, Fugh-Berman A. Physicians under the influence: social psychology and industry marketing strategies. J Law Med Ethics J Am Soc Law Med Ethics. 2013;41(3):665–72. [PubMed] [Google Scholar]
17. Brax H, Fadlallah R, Al-Khaled L, Kahale LA, Nas H, El-Jardali F, et al. Association between physicians’ interaction with pharmaceutical companies and their clinical practices: A systematic review and meta-analysis. PloS One. 2017;12(4):e0175493. [PMC free article] [PubMed] [Google Scholar]
18. Davari M, Khorasani E, Tigabu BM. Factors Influencing Prescribing Decisions of Physicians: A Review. Ethiop J Health Sci. 2018. November;28(6):795–804. [PMC free article] [PubMed] [Google Scholar]
19. Fickweiler F, Fickweiler W, Urbach E. Interactions between physicians and the pharmaceutical industry generally and sales representatives specifically and their association with physicians’ attitudes and prescribing habits: a systematic review. BMJ Open. 2017. September27;7(9):e016408. [PMC free article] [PubMed] [Google Scholar]
20. Lexchin JInteractions between physicians and the pharmaceutical industry: what does the literature say?CMAJ Can Med Assoc J J Assoc Medicale Can. 1993. November15;149(10):1401–7. [PMC free article] [PubMed] [Google Scholar]
21. Spurling GK, Mansfield PR, Montgomery BD, Lexchin J, Doust J, Othman N, et al. Information from pharmaceutical companies and the quality, quantity, and cost of physicians’ prescribing: a systematic review. PLoS Med. 2010. October;7(10):e1000352. [PMC free article] [PubMed] [Google Scholar]
22. Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. Cochrane Handbook for Systematic Reviews of Interventions[Internet].6th ed.Cochrane; 2019. [cited 2020 Jun 23]. Available from: www.training.cochrane.org/handbook [Google Scholar]
23. McGowan J, Sampson M, Salzwedel DM, Cogo E, Foerster V, Lefebvre C. PRESS Peer Review of Electronic Search Strategies: 2015 Guideline Statement. J Clin Epidemiol. 2016;75:40–6. [PubMed] [Google Scholar]
24. Bramer WM, Giustini D, de Jonge GB, Holland L, Bekhuis T. De-duplication of database search results for systematic reviews in EndNote. J Med Libr Assoc JMLA. 2016. July;104(3):240–3. [PMC free article] [PubMed] [Google Scholar]
25. Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016. October12;i4919. [PMC free article] [PubMed] [Google Scholar]
26. Parker-Lue SThe impact of reducing pharmaceutical industry payments on physician prescribing. Health Econ. 2020. March;29(3):382–90. [PubMed] [Google Scholar]
27. Bandari J, Turner RM, Jacobs BL, Canes D, Moinzadeh A, Davies BJ. The Relationship of Industry Payments to Prescribing Behavior: A Study of Degarelix and Denosumab. Urol Pract. 2017. January;4(1):14–20. [PMC free article] [PubMed] [Google Scholar]
28. Murrin SOPEN PAYMENTS DATA: REVIEW OF ACCURACY, PRECISION, AND CONSISTENCYIN REPORTING[Internet].Office of the Inspector General; 2018. August [cited 2019 Sep 26]. Report No.: OEI-03-15-00220.Available from: https://oig.hhs.gov/oei/reports/oei-03-15-00220.pdf
29. Ratain MJ. Forecasting unanticipated consequences of “The Sunshine Act”: mostly cloudy. J Clin Oncol Off J Am Soc Clin Oncol. 2014. August1;32(22):2293–5. [PMC free article] [PubMed] [Google Scholar]
30. Fleischman W, Agrawal S, Gross CP, Ross JS. Association of Pharmaceutical Manufacturer Payments to Physicians and Prescribing Dosage of Opioids. J Gen Intern Med. 2019;34(7):1074–6. [PMC free article] [PubMed] [Google Scholar]
31. Carey C, Lieber EMJ, Miller S. Drug Firms’ Payments and Physicians’ Prescribing Behavior in Medicare Part D[Internet].Cambridge, MA: National Bureau of Economic Research; 2020. February [cited 2020 Mar 27]. Report No.: w26751. Available from: http://www.nber.org/papers/w26751.pdf [Google Scholar]
32. Agha L, Zeltzer D. DRUG DIFFUSION THROUGH PEER NETWORKS: THE INFLUENCE OF INDUSTRY PAYMENTS. NBER Work Pap Ser[Internet].2019. October [cited 2020 Sep 28]; Available from: http://www.nber.org/papers/w26338 [Google Scholar]
33. Brunt CS. Physician characteristics, industry transfers, and pharmaceutical prescribing: Empirical evidence from medicare and the physician payment sunshine act. Health Serv Res. 2019;54(3):636–49. [PMC free article] [PubMed] [Google Scholar]
34. Mitchell AP, Winn AN, Dusetzina SB. Pharmaceutical Industry Payments and Oncologists’ Selection of Targeted Cancer Therapies in Medicare Beneficiaries. JAMA Intern Med. 2018. April9;178(6):854–6. [PMC free article] [PubMed] [Google Scholar]
35. Hartung DM, Johnston K, Cohen DM, Nguyen T, Deodhar A, Bourdette DN. Industry Payments to Physician Specialists Who Prescribe Repository Corticotropin. JAMA Netw Open. 2018. June1;1(2):e180482. [PMC free article] [PubMed] [Google Scholar]
36. Modi PK, Wang Y, Kirk PS, Dupree JM, Singer EA, Chang SL. The Receipt of Industry Payments is Associated With Prescribing Promoted Alpha-blockers and Overactive Bladder Medications. Urology. 2018. July;117:50–6. [PMC free article] [PubMed] [Google Scholar]
37. Qian J, Hansen RA, Surry D, Howard J, Kiptanui Z, Harris I. Disclosure of industry payments to prescribers: industry payments might be a factor impacting generic drug prescribing. Pharmacoepidemiol Drug Saf. 2017. July;26(7):819–26. [PMC free article] [PubMed] [Google Scholar]
38. DeJong C, Aguilar T, Tseng C-W, Lin GA, Boscardin WJ, Dudley RA. Pharmaceutical Industry-Sponsored Meals and Physician Prescribing Patterns for Medicare Beneficiaries. JAMA Intern Med. 2016. June20;176(8):1114–22. [PubMed] [Google Scholar]
39. Hadland SE, Cerdá M, Li Y, Krieger MS, Marshall BDL. Association of Pharmaceutical Industry Marketing of Opioid Products to Physicians With Subsequent Opioid Prescribing. JAMA Intern Med. 2018. 01;178(6):861–3. [PMC free article] [PubMed] [Google Scholar]
40. Khan R, Nugent CM, Scaffidi MA, Gimpaya N, Grover SC. Association of Biologic Prescribing for Inflammatory Bowel Disease With Industry Payments to Physicians. JAMA Intern Med. 2019. July8; [PMC free article] [PubMed] [Google Scholar]
41. Mehta HB, Moore TJ, Alexander GC. Association of Pharmaceutical Industry Payments to Physicians With Prescription and Medicare Expenditures for Pimavanserin. Psychiatr Serv Wash DC. 2020. August25;appips202000251. [PubMed] [Google Scholar]
42. Mitchell AP, Winn AN, Lund JL, Dusetzina SB. Evaluating the Strength of the Association Between Industry Payments and Prescribing Practices in Oncology. The Oncologist. 2019. February6;24(5):632–9. [PMC free article] [PubMed] [Google Scholar]
43. Orlowski JP, Wateska L. The effects of pharmaceutical firm enticements on physician prescribing patterns. There’s no such thing as a free lunch. Chest. 1992. July;102(1):270–3. [PubMed] [Google Scholar]
44. Morse E, Hanna J, Mehra S. The Association between Industry Payments and Brand-Name Prescriptions in Otolaryngologists. Otolaryngol--Head Neck Surg Off J Am Acad Otolaryngol-Head Neck Surg. 2019;161(4):605–12. [PubMed] [Google Scholar]
45. Zezza MA, Bachhuber MA. Payments from drug companies to physicians are associated with higher volume and more expensive opioid analgesic prescribing. PloS One. 2018;13(12):e0209383. [PMC free article] [PubMed] [Google Scholar]
46. Hollander MAG, Donohue JM, Stein BD, Krans EE, Jarlenski MP. Association between Opioid Prescribing in Medicare and Pharmaceutical Company Gifts by Physician Specialty. J Gen Intern Med. 2020. August;35(8):2451–8. [PMC free article] [PubMed] [Google Scholar]
47. Inoue K, Figueroa JF, Orav EJ, Tsugawa Y. Association between industry payments for opioid products and physicians’ prescription of opioids: observational study with propensity-score matching. J Epidemiol Community Health. 2020. April29; [PubMed] [Google Scholar]
48. Chren MM, Landefeld CS. Physicians’ behavior and their interactions with drug companies. A controlled study of physicians who requested additions to a hospital drug formulary. JAMA. 1994. March2;271(9):684–9. [PubMed] [Google Scholar]
49. Hayes MJ, Prasad V. Association between conflict of interest and published position on tumor-treating fields for the treatment of glioblastoma. J Cancer Policy. 2019. September;21:100189. [Google Scholar]
50. Lundh A, Lexchin J, Mintzes B, Schroll JB, Bero L. Industry sponsorship and research outcome. Cochrane Database Syst Rev. 2017. 16;2:MR000033. [PMC free article] [PubMed] [Google Scholar]
51. Peppercorn J, Blood E, Winer E, Partridge A. Association between pharmaceutical involvement and outcomes in breast cancer clinical trials. Cancer. 2007. April1;109(7):1239–46. [PubMed] [Google Scholar]
52. Liang F, Zhu J, Mo M, Zhou CM, Jia HX, Xie L, et al. Role of industry funders in oncology RCTs published in high-impact journals and its association with trial conclusions and time to publication. Ann Oncol Off J Eur Soc Med Oncol. 2018. August2;29(10):2129–34. [PubMed] [Google Scholar]
53. Tibau A, Bedard PL, Srikanthan A, Ethier J-L, Vera-Badillo FE, Templeton AJ, et al. Author financial conflicts of interest, industry funding, and clinical practice guidelines for anticancer drugs. J Clin Oncol Off J Am Soc Clin Oncol. 2015. January1;33(1):100–6. [PubMed] [Google Scholar]
54. Greenway T, Ross JS. US drug marketing: how does promotion correspond with health value?BMJ. 2017. May2;357:j1855. [PubMed] [Google Scholar]
55. Lexchin JThe relation between promotional spending on drugs and their therapeutic gain: a cohort analysis. CMAJ Open. 2017. September13;5(3):E724–8. [PMC free article] [PubMed] [Google Scholar]
56. Mahr MA, Hodge DO, Erie JC. Association between Industry Payments and Anti-vascular Endothelial Growth Factor Use in Medicare Beneficiaries. Ophthalmol Retina. 2017. February;1(1):19–24. [PubMed] [Google Scholar]
57. Morse E, Fujiwara RJT, Mehra S. The Association of Industry Payments to Physicians with Prescription of Brand-Name Intranasal Corticosteroids. Otolaryngol--Head Neck Surg Off J Am Acad Otolaryngol-Head Neck Surg. 2018. September;159(3):442–8. [PubMed] [Google Scholar]
58. Morse E, Fujiwara RJT, Mehra S. Industry Payments to Physicians and Prescriptions of Brand-Name Proton-Pump Inhibitors. Otolaryngol--Head Neck Surg Off J Am Acad Otolaryngol-Head Neck Surg. 2018. October16;194599818803337. [PubMed] [Google Scholar]
59. Rhee TG, Ross JS. Association Between Industry Payments to Physicians and Gabapentinoid Prescribing. JAMA Intern Med. 2019. July8;179(10):1425–8. [PMC free article] [PubMed] [Google Scholar]
60. Sharma M, Vadhariya A, Johnson ML, Marcum ZA, Holmes HM. Association between industry payments and prescribing costly medications: an observational study using open payments and medicare part D data. BMC Health Serv Res. 2018. April2;18(1):236. [PMC free article] [PubMed] [Google Scholar]
61. Singh P, Forman H, Adamson AS, Mostaghimi A, Ogdie AR, Oganisian A, et al. Impact of Industry Payments on Prescribing Patterns for Tumor Necrosis Factor Inhibitors Among Medicare Beneficiaries. J Gen Intern Med. 2018. October15;34(2):176–8. [PMC free article] [PubMed] [Google Scholar]
62. Singh N, Chang JS, Rachitskaya AV. Open Payments Database: Anti-Vascular Endothelial Growth Factor Agent Payments to Ophthalmologists. Am J Ophthalmol. 2017. January;173:91–7. [PubMed] [Google Scholar]
63. Taylor SC, Huecker JB, Gordon MO, Vollman DE, Apte RS. Physician-Industry Interactions and Anti-Vascular Endothelial Growth Factor Use Among US Ophthalmologists. JAMA Ophthalmol. 2016. 01;134(8):897–903. [PMC free article] [PubMed] [Google Scholar]
64. Goupil B, Balusson F, Naudet F, Esvan M, Bastian B, Chapron A, et al. Association between gifts from pharmaceutical companies to French general practitioners and their drug prescribing patterns in 2016: retrospective study using the French Transparency in Healthcare and National Health Data System databases. BMJ. 2019. November5;367:16015. [PMC free article] [PubMed] [Google Scholar]
65. Carrier M, Shadowen S. Pharmaceutical Product Hopping: A Proposed Framework For Antitrust Analysis[Internet].Health Affairs Blog. 2017. [cited 2020 Jun 30]. Available from: https://www.healthaffairs.org/do/10.1377/hblog20170601.060360/full/
66. Cole AL, Wood WA, Muluneh B, Lund JL, Elston Lafata J, Dusetzina SB. Comparative Safety and Health Care Expenditures Among Patients With Chronic Myeloid Leukemia Initiating First-Line Imatinib, Dasatinib, or Nilotinib. JCO Oncol Pract. 2020. March20;JOP1900301. [PubMed] [Google Scholar]
67. Paid to Prescribe? Exploring the Relationship Between Doctors and the Drug Industry. Sect. Special Committee on Aging, United States Senate, Serial No. 110-10Washington, D.C; June7, 2007. p. 128–31. [Google Scholar]
68. Korenstein D, Keyhani S, Ross JS. Physician attitudes toward industry: a view across the specialties. Arch Surg Chic Ill 1960. 2010. June;145(6):570–7. [PMC free article] [PubMed] [Google Scholar]
69. Fischer MA, Keough ME, Baril JL, Saccoccio L, Mazor KM, Ladd E, et al. Prescribers and Pharmaceutical Representatives: Why Are We Still Meeting?J Gen Intern Med. 2009. July;24(7):795–801. [PMC free article] [PubMed] [Google Scholar]
70. Brett AS, Burr W, Moloo J. Are gifts from pharmaceutical companies ethically problematic? A survey of physicians. Arch Intern Med. 2003. October13;163(18):2213–8. [PubMed] [Google Scholar]
71. Halperin EC, Hutchison P, Barrier RC. A population-based study of the prevalence and influence of gifts to radiation oncologists from pharmaceutical companies and medical equipment manufacturers. Int J Radiat Oncol Biol Phys. 2004. August1;59(5):1477–83. [PubMed] [Google Scholar]
72. Cain DM, Detsky AS. Everyone’s a little bit biased (even physicians). JAMA. 2008. June25;299(24):2893–5. [PubMed] [Google Scholar]
73. Altawalbeh SM, Ibrahim IA, Al-Shatnawi SF. Influence of pharmaceutical promotion on prescribers in Jordan. Int J Clin Pharm. 2020;42(2):744–55. [PubMed] [Google Scholar]
74. Annapureddy A, Minges KE, Henien S, Wang Y, Ross JS, Spatz ES, et al. Association between industry payments to physicians and device selection: A report from the NCDR ICD registry. Circulation[Internet].2018;138. Available from: http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L627103946 [Google Scholar]
75. Ayyash OM, Bandari J, Turner RM, Jacobs BL, Davies BJ. The relationship of physician payments from drug manufacturers to Medicare claims for abiraterone and enzalutamide. Can Urol Assoc J. 2016;10(9–10):S183. [Google Scholar]
76. Ayyash O, Bandari J, Turner R, Jacobs B, Davies B. Small effect of pharmaceutical industry payments to physicians on medicare prescription habits: Using abiraterone and enzalutamide. J Urol. 2017;197(4):e1013. [Google Scholar]
77. Bandari J, Turner RM, Jacobs BL, Davies BJ. An analysis of industry effects on prescriber behavior: Degarelix and denosumab. Can Urol Assoc J. 2016;10(9–10):S179–80. [Google Scholar]
78. Berger JT. Pharmaceutical industry influences on physician prescribing: gifts, quasi-gifts, and patient-directed gifts. Am J Bioeth. 2003;3(3):56–7. [PubMed] [Google Scholar]
79. Bourdette D, Van Leuvin S, Johnston K, Lei M, Hartung D. Industry payments to neurologists who commonly prescribe repository corticotropin gel (H.P. Acthar). Neurology[Internet].2017;88(16). Available from: http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L616550658 [Google Scholar]
80. Carlat DDOCTORS AND INDUSTRY Exploring the link between industry payments to doctors and prescribing habits. Bmj-Br Med J. 2014;349:3. [PubMed] [Google Scholar]
81. Catricalà AInternational non-proprietary name (INN) prescribing and conflict of interest. Ric E Prat. 2007;23(1):37–8. [Google Scholar]
82. Chua K, Li G, Stahl P, Hyams E. Are Industry Payments for Tadalafil Associated with Prescribing Habits Among Urologists and Primary Care Physicians?J Urol. 2019;201(4):E383–E383. [Google Scholar]
83. Duarte-Garcia A, Crowson CS, McCoy R, Ross J, Matteson EL, Shah N. Association between payments by pharmaceutical manufacturers and prescribing behavior in rheumatology. Arthritis Rheumatol. 2018;70:3379–80. [Google Scholar]
84. Dyer OIndustry payments to doctors drive surge in gabapentinoid prescribing, study finds. BMJ. 2019;366:14672. [PubMed] [Google Scholar]
85. Eisenberg MD, Stone EM, Pittell H, McGinty EE. The Impact Of Academic Medical Center Policies Restricting Direct-To-Physician Marketing On Opioid Prescribing. Health Aff (Millwood). 2020;39(6):1002–10. [PMC free article] [PubMed] [Google Scholar]
86. Eloy JA, Svider PF, Bobian M, Harvey RJ, Gray ST, Baredes S, et al. Industry relationships are associated with performing a greater number of sinus balloon dilation procedures. Int Forum Allergy Rhinol. 2017;7(9):878–83. [PubMed] [Google Scholar]
87. Fleischman W, Agrawal S, King M, Venkatesh AK, Krumholz HM, McKee D, et al. Association between payments from manufacturers of pharmaceuticals to physicians and regional prescribing: cross sectional ecological study. BMJ. 2016;354:i4189. [PMC free article] [PubMed] [Google Scholar]
88. Freemantle N, Johnson R, Dennis J, Kennedy A, Marchment M. Sleeping with the enemy? A randomized controlled trial of a collaborative health authority/industry intervention to influence prescribing practice. Br J Clin Pharmacol. 2000;49(2):174–9. [PMC free article] [PubMed] [Google Scholar]
89. Fujiwara RJT, Shih AF, Mehra S. Cross-sectional Analysis of the Relationship between Paranasal Sinus Balloon Catheter Dilations and Industry Payments among Otolaryngologists. Otolaryngol Head Neck Surg. 2017;157(5):880–6. [PubMed] [Google Scholar]
90. Glass HE. Do clinical grant payment practices in phase 3 clinical trials influence subsequent clinical investigator prescribing behavior?Dis Manag. 2004;7(1):77–87. [PubMed] [Google Scholar]
91. Gonzalez-Campoy JM. The physician-industry relation ship: lessons from the minesota experience. Endocr Pract. 2009;15(4):292–7. [PubMed] [Google Scholar]
92. Guo T, Sriram S, Manchanda P. “Let the Sunshine In”: The Impact of Industry Payment Disclosure on Physician Prescription Behavior. Mark Sci. 2020;39(3):516–39. [Google Scholar]
93. Hadland SE, Rivera-Aguirre A, Marshall BDL, Cerda M. Association of Pharmaceutical Industry Marketing of Opioid Products With Mortality From Opioid-Related Overdoses. Jama Netw Open. 2019;2(1):e186007. [PMC free article] [PubMed] [Google Scholar]
94. Hadland SE, Cerdá M, Earlywine JJ, Krieger MS, Anderson TS, Marshall BDL. Analysis of Pharmaceutical Industry Marketing of Stimulants, 2014 Through 2018. JAMA Pediatr. 2020;174(4):385–7. [PMC free article] [PubMed] [Google Scholar]
95. Hoffman MN. Pharmaceutical Detailing Is Not for Everyone: Side Effects May Include Sub-Optimal Prescribing Decisions, Compromised Patient Health, and Increased Prescription Drug Spending. J Leg Med. 2012;33(3):381–97. [PubMed] [Google Scholar]
96. Humphreys HConflicts of interest for medical practitioners. J R Coll Physicians Edinb. 2020;50(1):92–3. [PubMed] [Google Scholar]
97. Ichikawa I, Clayton EW. Doping Doctors: The Influence of the Marketing Departments of Pharmaceutical Companies on Physician and Researcher Behavior in Japan. Account Res. 2016;23(4):245–53. [PMC free article] [PubMed] [Google Scholar]
98. Khan R, Nugent CM, Scaffidi MA, Grover SC. Association of Biologic Prescribing for Inflammatory Bowel Disease with Industry Payments to Physicians. Gastroenterology. 2019;156(6):S–606. [PMC free article] [PubMed] [Google Scholar]
99. Lee AJ, Bandari J, Macleod LC, Davies BJ, Jacobs BL. Concentration of Opioid-Related Industry Payments in Opioid Crisis Areas. J Gen Intern Med. 2019;34(2):187–9. [PMC free article] [PubMed] [Google Scholar]
100. Lee A, Ayyash O, Maganty A, Macleod L, Bandari J, Jacobs B, et al. Pharmaceutical Payments for Opioids Significantly Favor Extended-Release Medication and Correlate with Physician Prescriptions. J Urol. 2019;201(4):E420–1. [Google Scholar]
101. Lee A, Ayyash O, Maganty A, Macleod L, Bandari J, Davies B, et al. Key opinion leaders motivate increased prescriptions among their local physicians. J Urol. 2019;201(4):e628. [Google Scholar]
102. Lichter PR. Physician-industry interactions and anti-vascular endothelial growth factor use among US ophthalmologists. Jama Ophthalmol. 2016;134(8):903–4. [PubMed] [Google Scholar]
103. Lo B, Grady D. Payments to physicians: Does the amount of money make a difference?JAMA - J Am Med Assoc. 2017;317(17):1719–20. [PubMed] [Google Scholar]
104. Marcum ZA, Chang CY, Barthold D, Holmes HM, Lo-Ciganic W. ASSOCIATION BETWEEN PHARMACEUTICAL INDUSTRY PAYMENTS TO PHYSICIANS AND PRESCRIBING OF BRANDED MEMANTINE AND DONEPEZIL COMBINATION. Value Health. 2020;23:S272–S272. [Google Scholar]
105. Maruf M, Sidana A, Purnell S, Fleischman W, Brancato SJ, Agrawal S, et al. Medications for urologic malignancies in the open payments data: Financial relationships between industry and urologists. J Clin Oncol[Internet].2017;35(6). Available from: http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L618006597 [Google Scholar]
106. Maruf M, Sidana A, Fleischman W, Brancato SJ, Purnell S, Agrawal S, et al. Financial Relationships between Urologists and Industry: An Analysis of Open Payments Data. Urol Pract. 2018;5(3):180–6. [Google Scholar]
107. McCarthy MDoctors who take company cash are more likely to prescribe brand name drugs, analysis finds. BMJ. 2016;352:i1645. [PubMed] [Google Scholar]
108. Mitchell AP, Winn A, Dusetzina S. Pharmaceutical industry payments and oncologist drug selection. J Clin Oncol[Internet].2017;35(15). Available from: http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L617388512 [Google Scholar]
109. Mitchell AP, Winn A, Lund JL, Dusetzina S. Duration of physician-industry relationships and prescribing changes in oncology. J Clin Oncol[Internet].2018;36(15). Available from: http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L625971791 [Google Scholar]
110. Modi P, Ingham M, Singer E, Chang S. Pharmaceutical industry payments and physician prescribing of urologic drugs. J Urol. 2017;197(4):e929. [Google Scholar]
111. Nalleballe K, Veerapaneni KD, Harada Y, Veerapaneni P, Arulprakash N, Lopez-Castellanos JR, et al. Trends of Industry Payments in Neurology Subspecialties. Cureus. 2020;12(7):e9492. [PMC free article] [PubMed] [Google Scholar]
112. Olch DI. Conflict of interest and physician dispensing. Internist. 1987;28(9):13–6, 24. [PubMed] [Google Scholar]
113. Pham-Kanter G, Alexander GC, Nair K. Effect of physician payment disclosure laws on prescribing. Arch Intern Med. 2012;172(10):819–21. [PMC free article] [PubMed] [Google Scholar]
114. PharmacoEconomics & Outcomes News. Drug Company Gifts to GPs May Influence Prescribing. Pharm Med. 2020;34(1):66–7. [Google Scholar]
115. Prescrire International. Gifts to doctors wield undue influence in France. Prescrire Int. 2020;29(215):135. [Google Scholar]
116. Rampulla CRelationships between physicians and industry. Rassegna Patol DellApparato Respir. 2007;22(4–5):253–7. [Google Scholar]
117. Rodwin MA. Medical commerce, physician entrepreneurialism, and conflicts of interest. Camb Q Healthc Ethics. 2007;16(4):387–97; discussion 439. [PubMed] [Google Scholar]
118. Roehr BPharma gifts associated with higher number and cost of prescriptions written. BMJ. 2017;359:j4979. [PubMed] [Google Scholar]
119. Schofferman J, Banja J. Conflicts of interest in pain medicine: Practice patterns and relationships with industry. Pain. 2008;139(3):494–7. [PubMed] [Google Scholar]
120. Serhiyenko V, Ravishanker N, Venkatesan R. Multi-stage multivariate modeling of temporal patterns in prescription counts for competing drugs in a therapeutic category. Appl Stoch Models Bus Ind. 2018;34(1):61–78. [Google Scholar]
121. Seto B, Juarez D, Singh D. The relationship between pharmaceutical manufacturer funding and prescribing patterns for anticoagulants in the United States. J Manag Care Spec Pharm. 2015;21:S55. [Google Scholar]
122. Sharma M, Johnson ML, Vadhariya A, Marcum ZA, Holmes HM. The association of prescriber characteristics with prescriptions for proton pump inhibitors in the medicare part D beneficiaries. Value Health. 2016;19(3):A317. [Google Scholar]
123. Singh P, Adamson A, Mostaghimi A, Foreman H, Barbieri J. Impact of industry payments on prescribing patterns for TNF-alpha inhibitors among Medicare beneficiaries. J Invest Dermatol. 2018;138(9):B6–B6. [Google Scholar]
124. Somai D, van Dijk L, Verheij R, de Bakker D. The effect of pharmaceutical marketing on the prescription of rofecoxib in Dutch general practice. Eur J Public Health. 2004;14(4):70–70. [Google Scholar]
125. Steinbrook RIndustry payments to physicians: Lessons from orthopedic surgery. Arch Intern Med. 2011;171(19):1765–6. [PubMed] [Google Scholar]
126. Steinbrook RIndustry Payments to Physicians and Prescribing of Brand-name Drugs. Jama Intern Med. 2016;176(8):1123. [PubMed] [Google Scholar]
127. Steinbrook R. Physicians, Industry Payments for Food and Beverages, and Drug Prescribing. JAMA. 2017;317(17):1753–4. [PubMed] [Google Scholar]
128. Steinbrook RIndustry Payments and Physician Prescribing. Jama Intern Med. 2019;08:08. [PubMed] [Google Scholar]
129. Taylor R, Giles J. Cash interests taint drug advice. Nature. 2005;437(7062):1070–1. [PubMed] [Google Scholar]
130. Tsai HJ. Physician-industry interactions: There is no such thing as a free lunch. Taiwan J Obstet Gynecol. 2008;47(2):252–5. [PubMed] [Google Scholar]
131. Vogel LPharma freebies for doctors linked to opioidprescribing habits. CMAJ Can Med Assoc J. 2019;191(7):E202. [PMC free article] [PubMed] [Google Scholar]
132. Yeh JS, Franklin JM, Avorn J, Landon J, Kesselheim A. Association of physicians’ financial relationships with pharmaceutical companies and their lipid-lowering medication prescribing patterns. J Gen Intern Med. 2015;30:S106. [Google Scholar]
133. Bandari J, Ayyash OM, Turner RM 2nd, Jacobs BL, Davies BJ. The lack of a relationship between physician payments from drug manufacturers and Medicare claims for abiraterone and enzalutamide. Cancer. 2017;123(22):4356–62. [PubMed] [Google Scholar]
134. Chua Kevin J, Li Gen, Stahl Peter J, Hyams Elias S. Receiving Industry Payments is Associated with Prescribing Habits of Tadalafil. Urol Pract. 2019;6(5):282–8. [Google Scholar]
135. Nguyen T, Andraka-Christou B, Simon K, Bradford WD. Provider-directed marketing may increase prescribing of medications for opioid use disorder. J Subst Abuse Treat. 2019;104:104–15. [PubMed] [Google Scholar]
136. Nguyen TD, Bradford WD, Simon KI. Pharmaceutical payments to physicians may increase prescribing for opioids. Addiction. 2019;114(6):1051–9. [PubMed] [Google Scholar]
137. Perlis RH, Perlis CS. Physician Payments from Industry Are Associated with Greater Medicare Part D Prescribing Costs. PLoS ONE Electron Resour. 2016;11(5):e0155474. [PMC free article] [PubMed] [Google Scholar]
138. Wood SF, Podrasky J, McMonagle MA, Raveendran J, Bysshe T, Hogenmiller A, et al. Influence of pharmaceutical marketing on Medicare prescriptions in the District of Columbia. PLoS ONE Electron Resour. 2017;12(10):e0186060. [PMC free article] [PubMed] [Google Scholar]
139. Yeh JS, Franklin JM, Avorn J, Landon J, Kesselheim AS. Association of Industry Payments to Physicians With the Prescribing of Brand-name Statins in Massachusetts. Jama Intern Med. 2016;176(6):763–8. [PubMed] [Google Scholar]
